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ANALYZING WHETHER PREVASCULARIZING ISLET SCAFFOLDS 





Objective: In today’s world, diabetes has become an ever-growing crisis, with no 
definitive cure yet found. In a report conducted by the American Diabetes Association in 
March of 2018, it was noted that 1.5 million Americans are diagnosed with diabetes each 
year (ADA, 2018). Insulin is both a limited and expensive source, with prices of Lispro, a 
rapid-acting insulin, costing upwards of $306 per 1000 units, to Glargine, a basal-analog 
insulin, costing $298 per 1000 units (McEwen et. al, 2017). Because of this, many 
diabetics are left with no alternatives to properly treat their blood sugars and maintain a 
healthy HbA1c level, a laboratory measure of glucose bound to hemoglobin that indicates 
a diabetic’s blood sugar over a two to three-month period (Mayo Clinic, 2018). Even with 
insulin treatment, diabetics can suffer from microvascular complications ranging from 
nephropathy, retinopathy, or even death thereafter if not properly cared for (Klein et. al, 
2005). In turn, many researchers have delved into analyzing and perfecting a potential 
treatment procedure known as islet transplantation that can serve to eliminate the 
necessity of insulin injections and pump devices, and replace the beta cells destroyed by 
complications from Type I diabetes.  
 
 vi 
Islet transplantation is the process of extracting healthy islets from the pancreas of 
an organ donor, purifying the islets in cell culture media that works to recover islet cells, 
known as islet isolation, and injecting the isolated islets into diabetic recipients whose 
beta cells are nonfunctional (Alejandro et. al, 2018). The goal of this procedure is to 
restore proper function of endogenous islets in the body, which contain beta cells that 
work to secrete insulin and better regulate the body’s glucose metabolism. While 
pancreatic islet transplantation can reverse diabetes, the process is inefficient, with many 
islets lost to hypoxemia before the islets become vascularized (Kumatzu et. al, 2018). We 
hypothesize that by prevascularizing islets ex-vivo, and using a gelatinous scaffold 
seeded with endothelial cells, one can avoid ischemic induced loss. This will ensure that 
islets are delivered the necessary oxygen and nutrients they need in order to restore 
endogenous function. By inserting this prevascularized device into the subcutaneous 
space of C57 BL/6 mice, islets can be surrounded by a vast blood network, allowing them 
to function similarly to when they are in the pancreas. If completed properly, this could 
ease the difficulty of diabetics continuously having to self-regulate their blood sugar 
levels by multiple injections of exogenous insulin each day. 
 
 Methods: Prior to implanting a prevascularized device into the mouse model, we 
isolated and purified healthy islets from the pancreases of C57 B/L 6 mouse donors, 
using the steps outlined in the Edmonton Protocol (Shapiro et. al, 2006). Each device 
could house approximately 300-400 islets, so about two to three mouse donors were used 
per vascularized graft implanted. In conjunction with IVIVA Medical, the functionalized, 
three-dimensional islet graft was created and contained a perfusable vascular bed to better 
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ensure islet survival and improve integration immediately after implantation. Mice were 
monitored daily to ensure the graft was stable inside the subcutaneous space and to 
ensure the mice were not experiencing any adverse reactions from the implant. On 
specified days post-implantation, the graft was explanted from the mouse, along with the 
surrounding tissue, to analyze the foreign body reaction experienced from the 
implantation and whether a vascular network formed. The tissue sample was then sent to 
the Histopathology Department for further processing and analysis. 
 Results: In all three groups in the study, foreign body reactions were expressed 
by the recruitment and presence of multiple cell lines, including macrophages, dendritic 
cells, and B and T lymphocytes. While immune cells proliferated, there were limited 
endothelial cells and islets present post-implantation, indicating the presence of 
hypoxemia, poor vascular formation, and a potent inflammatory response, ultimately 
leading to islet dysfunction. 
 Conclusion: While prevascularizing the scaffolds helped them better perfuse 
while in the subcutaneous space, we found that the inflammatory reaction, coupled with 
improper islet seeding, did not initially lead to islet graft survival. With modifications, we 
plan to create a stronger vascular network to surround the islet cells that would ensure 
their durability and survival in the long-term.  In utilizing this data, future research can 
work to better stabilize islet cells, with the end goal of translating this work into human 
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EXISTING TREATMENTS FOR TYPE I DIABETES 
 
There are two forms of diabetes: Type I and Type II. Type I diabetes involves the 
complete destruction of beta cells of the islets of Langherans, and requires the 
administration of exogenous insulin in order to maintain normoglycemia. Those with 
Type II diabetes, on the other hand, still have some of their beta cells intact, and in turn 
can produce some of their own insulin. However, they are unable to use that insulin 
efficiently to monitor their blood glucose levels (Castenada, 2019). Islets are groups of 
cells in the pancreas and are each comprised of about 1,000 cells working to monitor a 
person’s glucose metabolism. They consist of a combination of 30% glucagon-producing 
alpha cells that work to increase one’s blood glucose in times of fasting, of 60% insulin-
producing beta cells that are activated during times of feeding, and of 10% somatostatin-
producing delta cells, pancreating-polypeptide-producing cells, and ghrelin-producing 
cells that modulate the secretion of insulin and glucagon, respectively. (Xavier, 2018). 
A significant problem facing diabetes researchers today is the ability to 
successfully transplant islet cells into diabetic patients, whose beta cells are destroyed by 
an autoimmune response, compromising their ability to produce a vital hormone, insulin. 
It is normally secreted in a precise and highly regulated manner in response to increased 
blood glucose levels in the body postprandially through a mechanism involving 
membrane depolarization followed by the opening of L-type voltage-dependent Ca2+ 
channels and Ca2+ exocytosis (Komatsu et. al, 2013). Additionally, insulin is essential in 
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regulating carbohydrate, fat, and protein metabolism, and without it, patients can suffer 
from deadly consequences, including ketoacidosis and possibly death (Wolfsdorf, 2009). 
To address this ever-growing issue, research has been focused on developing innovative 
techniques to help with the proper transplantation of healthy islets without putting 
patients in harm’s way. However, this technology is not yet available. 
Currently, Type I diabetics have limited methods of treatment available to help 
regulate their blood sugar levels. The primary treatment option involves administration of 
exogenous insulin through injections or insulin pumps (Mayo Clinic, 2017). Prior to the 
discovery and availability of insulin, Type I diabetes was fatal, with no viable option 
available to help monitor glucose metabolism. Although insulin therapy is life-saving, it 
provides imperfect glucose control, resulting in a variety of long-term microvascular 
complications previously mentioned. Injections can be administered through syringes or 
refillable pens that can be taken throughout the day. This method of treatment has proven 
to be the standard because it ensures insulin is directly injected into the body and allows 
for simpler insulin delivery (ADA, 2003). However, it requires patients to more closely 
monitor their blood glucose and to take both short-acting and long-acting forms of insulin 
on a daily basis. Short-acting insulin is injected throughout the day when eating or 
experiencing high blood glucose levels, while long-acting insulin is injected before one 
goes to sleep to prevent hyperglycemia when in an inactive state (ADA, 2003). 
Continuous delivery by insulin pumps are a new and increasingly more common 
form of treatment. This device involves connecting a catheter to the body, usually in the 
abdominal or gluteal region, and delivering insulin through an automated device 
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throughout the day. This model may seem more beneficial, as it eliminates the necessity 
for daily injections and has calculated insulin dosages that act as the long-acting insulin 
to maintain one’s blood sugars (Shah et. al, 2016). Additionally, it can be coupled with a 
Continuous Glucose Monitor (CGM) which works to monitor one’s blood sugar levels. 
However, as with all technology, it has the potential to break down or suddenly 
malfunction, putting the diabetic’s life at risk if not able to deliver the required amount of 
insulin to maintain a healthy HbA1c (Mayo Clinic, 2017). 
There have also been developments in the closed-loop artificial pancreas system. 
It also uses a continuous glucose monitor, and when insulin is needed, it is delivered 
automatically through the device. Like the insulin pump and CGM device, this machine 
was created to help monitor diabetics’ blood sugar levels on a minute-by-minute basis, 
however is currently going through clinical trials to boost more promising results (Mayo 
Clinic, 2017). 
In the recent past, transplantation has become a promising novel form of 
treatment that could potentially obviate the necessity of relying on continual injections 
and technological devices to secrete insulin and maintain blood glucose levels, 
specifically for Type I diabetics. While Type II diabetics also have impaired glucose 
control, it is because of insulin resistance and decreased insulin sensitivity, and less so 
due to issues producing insulin (Cnop et. al, 2005). Therefore, islet transplantation is 
most likely to benefit Type I diabetics.  
 
There are various forms of transplantation currently under investigation. One such 
form is whole organ vascularized pancreas transplantation. This procedure involves the 
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immediate transplantation of an entire healthy pancreas from a deceased donor into a 
diabetic recipient, and is intended to transfer healthy islets, and in turn, promote proper 
insulin secretion. It has proven to be effective at restoring normoglyemia, promoting 
further islet graft survival, and even protecting against diabetic nephropathy (He et. al, 
2016). However, it is considered to be a major invasive surgery that presents with a 
variety of potential challenges, is difficult to perform, and may, like other organ 
transplantations, present infectious complications due to the need to administer 
immunosuppressive agents to prevent transplant rejection soon after the surgery (He et. 
al, 2016). 
Due to the increased risks presented by pancreas transplantation, research over the 
last thirty years has been more heavily focused into perfecting the science of islet 
transplantation. This procedure involves explanting the pancreas of a deceased organ 
donor, purifying the islets in vitro using the technical procedures outlined in the 
“Methods” section below, and transplanting them into a diabetic recipient, usually in 
either the liver, kidney capsule, or subcutaneous space. These sites on the body are 
thought to be best optimized in enabling proper diffusion of nutrients throughout the 
body, thereby enhancing islet graft survival (Chang et. al, 2004). The subcutaneous 
space, specifically, has been shown to be a common transplant site (Halberstadt et. al, 
2005). However, islets generally do not function in this location due to poor 





BRIEF HISTORY OF ISLET TRANSPLANTATION 
 Prior to islet transplantation, whole organ pancreas transplantation was the 
preferred method to restore islet function in diabetic patients. The goal was to allow for 
automatic secretion of insulin without the constant need of injections, insulin pumps, and 
glucose monitors. It came to fruition in 1965, with the first whole organ pancreas 
transplantation completed at the University of Minnesota (Bottino et. al, 2018). However, 
due to the inherent risks previously mentioned with the invasiveness of whole organ 
transplants and the accompanying immunosuppression, researchers have examined 
isolating islets from a donor’s pancreas and surgically transplanting them into a diabetic 
recipient through a single injection into the portal vein, where they lodge in the liver. 
Rather than transplanting an entire organ, millions of islets could be isolated through a 
demanding protocol involving pancreas explantation, digestion, and purification. The 
Edmonton Protocol, the term used for this islet transplantation procedure, was first 
successfully completed in 2000 by a small, dedicated team at the University of Alberta 
(Bottino et. al, 2018). The idea behind this procedure was to inject the islets into the 
portal vein, where the islets would then revascularize and maintain their function away 
from the pancreas, which is generally attacked by the immune system in diabetic patients 
(Dai et. al, 2020). Additionally, the Edmonton Protocol introduced the idea of using 
immunosuppressive drugs, including sirolimus and tacrolimus, to prevent the immune 
system from destroying the islets post-transplantation (Dai et. al, 2020). While these 
drugs are essential in maintaining islet durability and functionality, they do pose certain 
risks, including diarrhea, hypertension, anemia, and increased risk of cancer (Dai et. al, 
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2020). In light of these potential complications, researchers have focused on modifying 
the drug combinations used in islet transplantation procedures, with the goal of achieving 
immunotolerance of the islets in the body. Additionally, while it is customary to inject the 
islets into the portal vein, when islets lodge the bloodstream of the liver, an inflammatory 
response is initiated. Complement system activation initiates an innate immune response, 
compromising islet integrity and ultimately destroying the islets; this response has been 
terminal, often leading to patient death, and is called the Instant Blood Mediated 
Inflammatory Reaction (IBMIR) (Bennet et. al, 2000). It involves platelet and 
granulocyte consumption, coagulation, and complement activation, and can even lead to 
portal vein thrombosis, hepatic infarction, and portal hypertension. This was shown in a 
study of neonatal porcine islet cell transplantation conducted in 2016 that showed that up 
to 60% of islets were lost within a week of transplantation (Liuwantara et. al, 2016). 
 
 
Figure 1. Depiction of Islet Transplantation. The following diagram shows a common 
method of conducting an islet transplant, whereby healthy islets from a donor are injected 
into a recipient’s portal vein in the liver. The islets then trigger insulin secretion in 





COMMON SITES FOR ISLET TRANSPLANTATION 
There have been many studies evaluating the most effective sites on the body for 
islet transplantation procedures, including the liver, omentum, renal subscapular space, 
brain, thymus, testicles, bone marrow, and subcutaneous and pleural space (Zhu et. al, 
2018). The most common site, as previously mentioned, is the liver, primarily because it 
provides a point for optimal perfusion of nutrients and is a primary site of insulin 
utilization in the body (Rui, 2014). However, due to IBMIR and potential technical 
complications, other areas around the body have been tested to improve islet survival. 
Many studies have looked into the omentum as an optimal site for prevascularized 
islet transplants (Kim et. al, 2010). The omentum is heavily vascularized and has been 
shown to induce normoglycemia for up to a year. However, many islets are required to 
obtain proper blood glucose levels, and intestinal adhesion and obstruction were shown to 
have been observed post-transplantation (Kim et. al, 2010). 
Like the omentum, the kidney is also a popular site for islet transplantation. 
Benefits include that minimal islets are required to restore normoglycemia, strict glucose 
control, and a low operative mortality rate. However, the islets remain durable for only a 
short period of time due to exocrine contamination, and therefore multiple islet 
transplants may be required (Kim et. al, 2010). Additionally, this site offers too limited a 




The epididymal fat pad has also been heavily studied as a potential site for islet 
transplantation. In comparison to the omentum, this site has been shown to promote 
normoglycemia more quickly and with less exocrine contamination, and required islets to 
do so (Chen et. al, 2007). However, unlike the omentum, the epididymal fat pad does not 
provide optimal portal drainage, which may hinder islet durability and survival by not 
providing an adequate blood supply (Chen et. al, 2007). 
For our study, we chose to analyze the impact of implanting islets into the 
subcutaneous space. As previously mentioned, the subcutaneous space has been shown to 
provide a relatively larger surface area for easier explantation of the graft in comparison 
to other sites, such as seen in an intraperitoneal islet transplantation (Villa et. al, 2017). 
Additionally, because IBMIR is less likely to occur in the subcutaneous space, we 
believed that this site was the most optimal to enhance islet survival. Even though the 
subcutaneous space has been shown to be poorly vascularized and poorly protects the 
islets from hypoxemia, it has been shown that, if the islets were prevascularized in a 




 In the last few years, attempts have been made to prevascularize scaffolds for islet 
transplantation to better promote islet graft survival. In 2015, Pepper et. al conducted a 
study in which researchers placed a subcutaneous cell pouch device containing 
endothelial cells into the subcutaneous space. This was followed by the injection of islets 
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to help prevent an inflammatory response before the generation of a vascular network 
(Pepper et. al, 2015). This technique was thought to be more beneficial in preventing the 
islets from dying due to poor vascularization and hypoxemia, thereby compromising their 
ability to restore normoglycemia. 
 Even more recently, attempts have been made at seeding islets and endothelial 
cells into one scaffold, and implanting it subcutaneously. A study was completed 
whereby such a scaffold was implanted into a murine model and showed the formation of 
a capillary network 21-days post-implantation (Vlahos et. al, 2017). Additionally, insulin 
staining confirmed islet survival, and restoration of normoglycemia appeared successful 
(Vlahos et. al, 2017). Normoglycemia was also observed in similar studies conducting 
islet transplants subcutaneously (Hirabaru et. al, 2015; Buitinga et. al, 2016; Nibbelink et. 
al, 2017). In all the studies mentioned, scientists infused free islets subcutaneously as a 
comparison, however the islets died soon thereafter due to poor vascularization and 
hypoxemia, and the mice were unable to achieve proper glucose control. This showed the 
value of prevascularizing the implanted devices, and their positive impact in achieving 
islet survival. 
This is similar to our study, whereby we seeded islets and endothelial cells into a 
scaffold in the vascular and parenchymal spaces, respectively, and implanted it 
subcutaneously to analyze whether the formation of the vascular network and any 
ensuing foreign body reactions (FBR) would be affected. However, our study also looks 
to maintain islet function and vascularization more long-term, prevent the necessity of 
further transplantations once the islets cease to function, and more closely analyze the 
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immune cell populations proliferating around the prevascularized islet scaffolds once 
implanted. Our goal is to provide a method for better understanding the relationship 
between subcutaneous islet transplantation and improved revascularization for future 
testing in both animal and human models. 
 
CURRENT TRENDS AND THE PRESENT STUDY 
The objective of our study was to test whether the use of a prevascularized device 
would promote islet graft durability and survival in a subcutaneous mouse model. The 
device itself consists of two spaces, each separated by a thin basement membrane. One 
side of the device is the vascular space, which contains the sourced endothelial cells and 
serves to form a vascular network, while the other side consists of the parenchymal space, 





Figure 2. Implanted Device. Pictured above is a diagram of the implanted device with 
both the vascular space and parenchymal space present. The vascular space will contain 
the endothelial cells, while the parenchymal space will contain the islets, each separated 
by a thin basement membrane. Upon glucose stimulation in the vascular space, glucose 
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will cross the basement membrane and enter the parenchymal space, and stimulate the 
islets to secrete insulin. The insulin will then cross the basement membrane and enter the 
vascular space, and diffuse throughout the rest of the body, forming a strong vascular 
connection (Jaramillo, 2019). 
 
 
The study consisted of three groups of C57 BL/6 mice, with each group 
comprised of five mice. All groups would receive a different device implanted into the 
skin: (1) an acellular device without sourced endothelial cells nor islets, (2) a cellular 
device with endothelial cells in the vascular space but without islets, and (3) a cellular 
device with endothelial cells in the vascular space and islets present in the parenchymal 
space. 
The first group of mice had an acellular device implanted into the subcutaneous 
space, located on the lower back, to evaluate the host response to the islet graft and its 
integration into the body. Because the scaffolds were foreign substances implanted into 
the body, it was essential to evaluate whether there was an inflammatory response caused 
by the device post-implantation. This has been shown in similar studies when an immune 
response was triggered after foreign islets were transplanted into diabetic recipients from 
organ donors (Belle and Herrath, 2008). To better prevent an immune response, we chose 
to use C57 BL/6 mice as both the donors and recipients of the islets, as the islets would 
not be seen as foreign once implanted, and trigger a foreign body reaction. 
The term “foreign body reaction” describes the response the tissue experiences 
after a foreign particle enters the body. This can vary from acute or chronic inflammation 
surrounding the implanted device, to rejection of the device in the body (Anderson et. al, 
2007). Oftentimes, the acute inflammatory response triggers neutrophil and macrophage 
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infiltration followed by an accompanying adaptive immune response that triggers the 
presence of B and T cells. Both responses result in fibrosis and subsequent islet death 
(Anderson et. al, 2007). In previous studies analyzing the impact of inflammation in Type 
I diabetes, various immune cells, including macrophages and lymphocytes, were 
observed to induce an inflammatory response and impair islet function and survival 
(Willcox et. al, 2009). This led to further insulitis, and an inability to obtain 
normoglycemia without exogenous insulin intake. By observing these immune cell 
populations surrounding our scaffolds, we could better understand what could lead to 
potential graft rejection post-implantation. 
The purpose of implanting acellular scaffolds was to analyze the foreign body 
reaction in response to the scaffold post-implantation. A porous and a nonporous scaffold 
were implanted for the first group. The porous scaffold allowed for better perfusion of 
glucose during in vitro testing, however showed poor protection against an innate 
immune response. The nonporous scaffold, which better protected against an innate 
immune response, served as a control to see if the addition of a porous membrane 
improved vascularization post-implantation. The subcutaneous space was chosen for our 
study because it has a large surface area and grants easy access and monitoring. 
Additionally, it allows for more optimal retrieval of the graft for further analysis of the 
surrounding cell lines to determine the level of inflammation and viability of the islets 
and endothelial cells (Smink et. al, 2018). 
The second group of mice had a cellular device with endothelial cells in the 
vascular compartment implanted into the subcutaneous space. The importance of this 
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group was to evaluate the rate of perfusion throughout the entire islet graft, in addition to 
the benefits of prevascularization in maintaining islet graft survival. 
The third group of mice was implanted with a cellular device prevascularized with 
endothelial cells and contained islets in the parenchymal space to evaluate whether 
prevascularization improves islet engraftment and functionality. The islets were provided 
by the islet isolation, digestion, and purification methods mentioned in the “Methods” 
section below. 
 To evaluate the FBR and the integration of the scaffold into the tissue, the device 
from each mouse was explanted after specific time points, including from one, to two, to 
seven, to fourteen, to twenty-eight days post-implantation. This allowed the analysis of 
the kinetics of the FBR in each mouse model, and identification of which cells immune 
cells proliferated in response to the implantation of the device. 
 
 
Figure 3. Islet Scaffold Seeding. Pictured above is the pancreas scaffold implanted into 
the C57 BL/6 mice, measured at 3 mm by 5 mm. The scaffold is made from a porcine gel 
and was implanted into the subcutaneous space. Seeding of the islets entails proper 







 Histological analysis was completed post-explantation to analyze any foreign 
body reactions the tissues experienced and to better understand the connection between 
the device and the body that would enable proper perfusion and diffusion of insulin and 
oxygen. Markers were selected to determine the presence of diverse cell lines, including 
F4-80, CD3, pDC-A1, and von-Willebrand Factor. These particular cell lines were 
chosen because of their relative abundance post-islet transplantation (Xia et. al, 2017). 
 
SPECIFIC AIMS 
The aim of this paper is to analyze whether seeding islets into a prevascularized 
device containing endothelial cells can better enhance long-term islet survival. To date, 
most diabetic medical care focuses on seeking treatments, mainly insulin therapy and a 
balanced diet and exercise routine, to better one’s lifestyle choices and improve HbA1c 
levels. Reasons for this include that there is a limit to the number of beta cells available 
for proper islet transplantation, in addition to complications in delivery of the nutrients 
and insulin by macro-and-microencapsulation transplantation devices (Hwa and Weir, 
2018). 
As discussed earlier, the primary goal of this research has been to better enable 
islet graft survival using prevascularized devices in diabetic recipients. Additionally, the 
objective of this paper is to analyze the various methods of islet transplantation, and 







As described above, 3 groups were prepared for transplantation. While Groups 1 
and 2 of the study did not require the seeding of islets into the parenchymal space, for 
Group 3 of the study, it was essential to test that, when exposed to glucose, the seeded 
islets would stimulate insulin ex-vivo through the parenchymal space. Prior to implanting 
the islets, we exposed them to varying concentrations of glucose, ranging from 3.3 mM to 
16.7 mM, and the amount of insulin secreted was measured thereafter. The step-by-step 
process of the glucose-stimulated-insulin-secretion analysis is detailed below. 
 
 
IN VITRO STUDIES 
 In-vitro studies were conducted by IVIVA Medical Group to analyze the ability of 
the devices in improving both the perfusion and diffusion of nutrients throughout the 
body. Their studies followed the Department of Transplantation Surgery at the University 
of Wisconsin’s protocol, working to assess the functional potency of the purified islets by 
measuring their ability to secrete insulin upon glucose stimulation. Kreb’s Buffer, a 
solution comprised of 1260 mM NaCl, 25 mM KCl, 250 mM NaHCO3, 12 mM 
NaH2PO4, 12 mM MgCl2, and 25 mM CaCl2, was used to maintain the islet tissue 
(CSHP, 2020). Islets were subjected to varying glucose concentrations, ranging from 3.3 
mM glucose to 16.7 mM glucose, to measure the ability of the islets to secrete insulin 




 The process began by taking 150 islet particles explanted during the islet isolation 
process and placing them in a Quality Control tissue culture incubator to keep them in a 
contaminated-free environment prior to GSIS testing. Following the incubator, the islets 
were pipetted into a p100 petri dish containing 20 ml of pre-warmed culture media. 25 ml 
of the 3.3 mM glucose solution was then prefilled into two petri dishes and marked 
“Basal #1” and “Basal #2”, with 0.5 ml of the 3.3 mM glucose solution placed into five 
labeled cryovials, and 0.5 ml of the 16.7 mM glucose solution placed into another five 
labeled cryovials. The cryovials were then placed into a 37-degree Celsius tissue culture 
incubator, while the petri dish containing the islets was placed onto an inverted 
microscope. A Pasteur pipet was connected to a micrometer syringe, and the 150 islet 
particles were picked and placed into the petri dish labeled Basal #1. Careful 
consideration was taken to pick up as little media as possible. 
 The Basal #1 petri dish, containing the islets, and the Basal #2 petri dish were 
then placed into a 37-degree Celsius culture incubator and incubated for thirty minutes. 
Thereafter, the Basal #1 petri dish was placed on the inverted microscope, and using the 
Pasteur pipet with the connected micrometer syringe, the islets were transferred from the 
Basal #1 petri dish to the Basal #2 petri dish, and put on the inverted microscope. Eight to 
ten islets were then handpicked using the Pasteur pipet and transferred to each of the ten 
cryovials, with careful attention to minimize the amount of media transferred when 
collecting the islets. 
 The islets were incubated in a 37-degree Celsius water bath for one hour, shaken 
gently, and placed in a microcentrifuge. 0.3 mL of the supernatant was then removed and 
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placed in the labeled microfuge tubes, while the islets were saved for DNA extraction or 
stored at -80-degrees Celsius. 
 ELISA was conducted using the supernatant sample to test the ability of the islets 
in secreting insulin upon glucose stimulation. ELISA worksheets containing insulin 
values were attached to a Glucose-Stimulated-Insulin-Secretion Assay Worksheet. DNA 
was then extracted from the islets that remained in the cryovials and quantified. DNA 
quantification worksheets containing raw fluorescence values and calculated DNA 




 Group 3 of the study involved subcutaneous implantation of a prevascularized 
device with endothelial cells in the vascular space, with the addition of islets in the 
parenchymal space, into C57 BL/6 mice. For Pancreas Isolation procedures, the 
Department of Transplantation Surgical Research at Massachusetts General Hospital 
follows a step-by-step protocol outlined below of isolating healthy islets from a donor 
mouse model. 
Prior to beginning the islet isolation procedure, 4 mL of 6x Dispase Low Liberase 
(collagenase) enzyme would be thawed and diluted with 20 mL Hanks Balanced Salt 
Solution (HBSS) to make 1x DL Liberase. HBSS is used to maintain constant pH and 
durability of the islets, while Dispase Low Liberase is a commercially available 
collagenase enzyme used to isolate the pancreatic tissue in lieu of culturing islets in the 
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following pancreas digestion and purification steps outlined below (Nikolic et. al, 2010). 
These solutions are important in enzymatically digesting the pancreatic tissue connecting 
the islets to the exocrine tissue, and in preparing the islets for further processing. 
Following the preparation of Liberase, we began the isolation procedure. 
A healthy C57 BL/6 mouse was taken and placed in a chamber filled with 3.0 mL 
Isoflurane, a common anesthetic used in mouse procedures. A foot pinch was conducted 
to ensure the mouse was properly anesthetized. If the mouse moved, then it was 
indicative more anesthesia was required. 
Once the mice were fully anesthetized, they were euthanized by cervical 
dislocation. The abdomen was then sprayed with 70% ethanol, and each mouse was 
placed supine with its head facing the researcher. Using a large pair of scissors, an 
incision was made at the abdominal flap, pulling the skin and abdominal wall caudally to 
expose the abdominal contents. The intestines were moved to the left to help locate the 
gall bladder and bile duct. The section of the common bile duct where it enters the 
duodenum was clamped, adjacent to where the pancreatic duct joins it. This clamp was 
essential in ensuring all of the injected Liberase would enter the pancreas and that none 
would leak out to the intestine (Carter et. al, 2009). The common bile duct was then 
cannulated with a 30-gauge needle distally to where the cystic duct and common hepatic 
duct join, and infused with 2-2.5-mL of Liberase with HBSS into the pancreas via the 
bile duct. The pancreas was then carefully excised by pulling it away from the 





 Once all the pancreases were isolated, they were placed into conical tubes before 
being placed in a water bath at 37.4 degrees Celsius for 16 minutes. The tube was then 
removed and quenched with Dulbecco’s Modified Eagle’s Medium (DMEM) media with 
5% FBS solution and shaken vigorously up and down. The DMEM/5% FBS solution was 
added to help maintain a constant pH level and the durability of the pancreas. A lamp was 
then used to make sure the tissue was completely digested and that there were no large 
pieces of tissue remaining in the tube. The tube was then filled up to the top with DMEM 
before centrifugation to wash out the digestion enzymes and cellular debris. 
 
PANCREAS WASHING 
The tube was centrifuged at 1300 rpm for 1 minute, followed by aspiration of the 
wash. 10 mL of DMEM media was then added to the tube, which was then shaken with 
the cap on to break up the pellet. A tea strainer was wetted with DMEM media, and the 
islets and media solution were poured through the tea strainer into a new conical tube to 
remove any remaining extraneous chunks of tissue. 10 mL of media was added to the 




Once the third rinsing was completed, 10 mL of 1.11 islet gradient solution was 
added to the pellet and the solution was vortexed to break it up further. The 1.11 density 
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gradient solution worked to clearly separate and distinguish the islet layer from the 
exocrine tissue for further purification. Following the addition of the density gradient 
solution, 10 mL of non-FBS DMEM media was slowly pipetted down the side of the tube 
on top of the heavy gradient solution and islets layer. Non-FBS media was used for this 
step to prevent the islets from sticking to the conical tube before transplantation. 
The conical tube was then centrifuged with low acceleration and low deceleration 
at 2000 rpm for 18 minutes to avoid disruption of the gradient. A transfer pipet was then 
wetted with fresh DMEM media with 5% FBS to avoid losing islets in the pipette. The 
islets were removed from the interface between the heavy and middle layer, with careful 
attention paid to ensure no islets were lost, and placed into a fresh conical tube. The 
conical tube was then filled to the top with DMEM media and centrifuged at 1300 rpm 
for one minute with fast acceleration and deceleration. The supernatant was aspirated, 
and the tube was then tapped to break up the pellet. The rinsing step was repeated once 
more. 
 The pellet was then resuspended with 200 microliters of media using a 1000 mL 
pipet. A 60 x 15 mm petri dish was then filled with DMEM media, and the islets were 
transferred to the petri dish. This step was repeated with the conical tube to confirm that 
all the islets were collected. Throughout the procedures, the purity would not exceed 
80%, so a 70-micrometer mesh was used and placed upside down in the petri dish bottom 
and wet with media to capture any remaining islets. The islets were then viewed under a 
microscope and the purity was further assessed. Once the islet isolation process was 
completed, they were delivered to the IVIVA Medical team to be seeded into the 
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parenchymal compartment of the scaffolds for future transplants into the subcutaneous 
space of the mice. 
  
DEVICE IMPLANTATION 
The scaffold was comprised of a gelatinous material, with a 1-10 micrometer 
thick basement membrane separating both the vascular and parenchymal spaces that are 
10-100 micrometers in size and roughly 250 micrometers in size, respectively. Roughly 
300-400 islets fit into each vascularized scaffold in the parenchymal space for 
implantation. 
 For Group 1, an acellular device was implanted, consisting of a porous scaffold 
and a nonporous scaffold each placed into the subcutaneous space located near the 
inferior portion of the back. Mice were placed into a glass container connected to 
isoflurane, a chemical used to anesthetize mice. Once the mice were assuredly 
anesthetized, two incisions, each on the left and right side of the subcutaneous space six-
centimeters long by one-centimeter wide, were made. This was followed by placement of 
the nonporous scaffold on the left side followed by the porous scaffold on the right side. 
The use of acellular scaffolds served as a control to test whether adding endothelial cells 
into the vascular compartment truly improved revascularization post-implantation. 
 Groups 2 and 3 were used to better compare the immune response between adding 
vascularized scaffold with and without islets. We added vascularized scaffolds without 
islets (Group 2) and vascularized scaffolds with islets (Group 3) into the left and right 
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side of the subcutaneous space, respectively, in a surgical procedure identical to that of 





 For all three groups of the study, the device was explanted after specific time 
points, including one-day, two-day, one week, two weeks, and four weeks post-
implantation. This was essential in helping evaluate the diverse foreign body reactions 
experienced by the mouse, in addition to assessing the accompanying connection between 
the device and the surrounding tissue at various time points. 
Each explant began with anesthetizing the mouse, followed by euthanizing it by 
cervical dislocation. Each device was explanted by making a circular incision around the 
subcutaneous space, and the device and surrounding skin were taken out and placed in 
paraformaldehyde solution for two hours. This was completed to allow the tissue and 
device to fixate and come together. When explanting the tissue, a suture was used to 
tether the device and tissue together to help prevent the device from sliding off during 
tissue processing. Following this step, the tissue samples were transferred over to a 
conical tube containing phosphate buffered saline to maintain a constant pH of 6.4 before 
being processed for histology. 
 
HISTOLOGY 
 After the devices were explanted from the mice, histological analysis was 
conducted by the Histopathology Core in the Department of Transplantation at MGH to 
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analyze the vascular connection generated between the device and the body, in addition 
to the foreign body reaction experienced by the mice post-implantation. As previously 
mentioned, it was believed that, after implanting the prevascularized device into the 
subcutaneous space, which is itself heavily vascularized, diffusion of insulin and other 
important nutrients would be improved throughout the rest of the body. By analyzing the 
proliferation of diverse cell populations like the ones mentioned, we believed that we 
could better understand whether the scaffold was accepted or rejected by the body upon 
analysis of the immune response. 
 Several markers were selected to indicate whether certain cell lines were present 
that could induce an inflammatory response, including macrophages, neutrophils, 
lymphocytes, dendritic cells, and fibroblasts. Specifically, macrophages play an integral 
role in initiating the inflammatory response, and thereby impeding islet cell function, by 
inhibiting insulin secretion in response to glucose stimulation (Uno et. al, 2007). 
Therefore, F4-80, a marker that detects the presence of macrophages, was selected. 
 Markers were also selected to analyze whether neutrophils were present as 
elements of the foreign body reaction. Neutrophils have reportedly been correlated with 
Type I diabetes, and work to secrete IL-1β, which can impair islet functionality and 
durability that negatively affects insulin secretion (Kanak et. al, 2014). Ly6G is a 
common marker used to detect neutrophils, and was selected for the present study (Daley 
et. al, 2007). 
 To detect for the presence of lymphocytes, several markers were selected. CD3 
was chosen as a marker to detect for the presence T cells, while CD20 was the chosen 
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marker to detect for the presence of B cells. An abundance of lymphocytes is indicative 
of an adaptive immune response, which can impair the functionality and durability of the 
islets in the body (Lewis et. al, 2002). 
 Dendritic cells are also commonly present post-islet transplantation. They are 
antigen presenting cells that work to initiate an innate immune response, and hence 
inflammation, when an infection or injury occurs. The two types identified in mammals 
are myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) (Masten et. 
al, 2006). Myeloid dendritic cells are also divided into two categories, namely mDC-1, 
which stimulates T cells, and mDC-2, which fights off infections (Chistiakov et. al, 
2014). pDCs have similar qualities as mDCs, however are primarily known for secreting 
interferon-alpha, which works to regulate immune responses (Jegalian et. al, 2009). Well-
known markers used to differentiate between both types of dendritic cells include BDCA-
1, BDCA-3, and BDCA-4, however we chose pDCA-1 as a marker because it has been 
shown to best distinguish the presence of plasmacytoid dendritic cells in the surrounding 
tissue (Masten et. al, 2006). Additionally, pDC-A1 was selected to properly detect a 
plasmacytoid dendritic cell. 
Lastly, a critical indicator of a foreign body reaction is the presence of fibroblasts 
in response to damaged tissue. This generally results in a sample showing thicker 
connective tissue, with an increased presence of multiple cell lines, including 
macrophages and lymphocytes. Anti-Vimentin was the marker chosen, as it detects for 
the presence of vimentin monomers. Vimentin is a group of proteins that dimerize to 
form the cytoskeleton of fibroblasts and endothelial cells (Divanyan et. al, 2019). This 
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antibody helped us analyze whether fibrosis was present, and gain a further 
understanding of whether damage to the host’s skin impacted the device’s durability. 
 The devices implanted in Groups 2 and 3 were prevascularized with endothelial 
cells to evaluate whether the survival and functionality of the islet graft improved post-
implantation with a pre-formed vascular network. von-Willebrand Factor, a marker 
similar to anti-CD31 that can detect endothelial cells and can suggest angiogenesis, was 
selected to determine the formation of a vascular network, in addition to the impact of the 
endothelial cells on the perfusion of nutrients throughout the body (Giatromanolaki et. al, 
1997). Angiogenesis is integral for ensuring the islets maintain a strong connection with 
the host, and can help answer the initial hypothesis about whether prevascularization can 
promote islet survival and durability. 
 
INFLAMMATORY SCORE 
 While conducting histological analysis to assess the foreign body reaction on the 
host, an inflammatory score was assigned based on the presence of diverse cell lines, 
including macrophages and neutrophils, the degree of lymphocyte infiltration, and the 
degree of fibrosis. The score for each category was based on a scale from 0-3. A score of 
0 for the presence of cell lines indicates that no cells are present, while a score of 1 
indicates that there are some cells scattered around the scaffold. A score of 2 indicates 
that numerous cells are located at the focal interfaces of the scaffold, while a score of 3 
indicates that numerous cells are surrounding the scaffold. 
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 A score of 0 analyzing the degree of lymphocytic infiltration indicates that no 
visible cells infiltrated the skin, while a score of 1 indicates a minor or moderate 
infiltration. A score of 3 indicates an extensive infiltration, with an increasing number of 
B and T lymphocytes surrounding the skin. 
 A score of 0 analyzing the degree of fibrosis indicates that there is no fibrosis 
present, with no visible thickness surrounding the skin, while a score of 1 indicates that 
the tissue is one to two cell layers thick. A score of 2 indicates that the skin has three to 
five cell layers visible, while a score of 3 shows more than five cell layers in thickness. 
An overall score was calculated from the combination of these three factors, with a 
















HEMATOXYLIN AND EOSINOPHIL STAINS 
 Tissue processing and analysis for all groups was completed post-explantation. 
Prior to conducting immunohistochemistry stains, hematoxylin and eosinophil (H&E) 
stains were completed to better understand the overall inflammatory response 
experienced by the tissue and any underlying vasculature created post-implantation of the 
scaffold. In previous islet transplantation studies, H&E stains were especially important 
not only in detecting immune responses and microvasculature present surrounding the 
tissue, but also in confirming the presence of islet cell survival post-transplantation 
(Campbell-Thompson, 2012). Below are images of the H&E stains for all three groups of 
the study, all taken at 40x magnification. Images for certain days post-explantation are 
not present due to an inability to provide proper visualization of the inflammatory 
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Figure 4. Acellular Nonporous Scaffold H&E Stains for Group 1 Between Days 1-28 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
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Figure 5. Acellular Porous Scaffold H&E Stains for Group 1 Between Days 1-28 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 




 Figures 4 shows representative images of H&E stains completed for mice from 
Group 1 receiving the acellular nonporous scaffolds post-implantation, while Figure 5 
shows representative images of H&E stains completed for mice from Group 1 receiving 
the acellular porous scaffolds post-implantation. Inflammation was observed to have 
increased over the 28 days the scaffold was in the body of the mice, especially in Day 14 
post-implantation (Figures 4D and 5D, respectively). As mentioned previously, it was 
hypothesized that the porous scaffold would allow for better perfusion and integration 
into the body in comparison to the nonporous scaffold, however would not be as effective 
in preventing an inflammatory response. Based on Figures 5A-5E, this was not the case, 
as there were similar aggressive foreign body reactions in both scaffolds. There is an 
increased recruitment of immune cells and fibrosis over time in the first several days 
post-implantation, especially days 1 and 2 post-implantation (Figure 5A and 5B, 
respectively). This was thought to have played a role in the decreased formation of 
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Figure 6. H&E Stains for Group 2: Vascularized Scaffolds without Islets Between 
Days 1-28 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-





Figures 6A-6E show representative images of H&E stains completed for the group of 
mice that received the vascularized scaffolds with endothelial cells present in the vascular 
space and without islets in the parenchymal space post-implantation. While the scaffold 
is not clearly visible in every picture, there is a clear presence of immune cell 
proliferation over time, especially visible in Days 14 and 28 post-implantation (Figures 
6D and 6E, respectively). After completing immunohistochemistry for these slides 
(Figures 8-29), we were able to detect the specific immune cells recruited in response to 
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Figure 7. H&E Stains for Group 3: Vascularized Scaffolds with Islets Days 1-28 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
Day 7 Post Implantation. (D.) Day 14 Post-Implantation. (E.) Day 28 Post-Implantation. 
 
Figures 7A-7E show representative images of the H&E stains completed for the 
group of mice receiving vascularized scaffolds that contained endothelial cells in the 
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vascular space and islets in the parenchymal space (Group ???). The tissue samples above 
responded similarly to the tissue samples of mice implanted with vascularized scaffolds 
without islets, as seen by the similar immune cellular proliferation. Seeding islets into the 
parenchymal space was especially valuable in being able to determine whether the 
inflammatory response caused graft rejection. Our original hypothesis was that if islets 
and endothelial cells were present in the histology in Days 1 and 2 post-implantation, and 
died or disappeared in the later time points, then this would be a clear sign of rejection of 
the scaffold by the subcutaneous tissue. However, based on the histology above in Figure 
7A, islets were not present on Day 1, so we could not definitively conclude that the 
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Figure 8. CD20 Stains for Group 1: Presence of B Cells Between Days 1-14 Post-
Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) Day 7 
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Figure 9. CD20 Stains for Group 2: Presence of B Cells Between Days 1-28 Post-
Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) Day 7 
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Figure 10. CD20 Stains for Group 3: Presence of B Cells Between Days 1-28 Post-
Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) Day 7 





Figures 8-10 show representative images of slides stained with the B-cell marker 
CD20, and indicate the presence of B cells, in all three groups post-implantation. Over 
the 28-day period, there seems to be an increase in the recruitment of B cells to the tissue 
surrounding the graft in all three groups. This suggests the occurrence of a tissue-specific 
immune response leading to T cell proliferation upon the implantation of the scaffold 
(Radenkovic et. al, 2016), and signifies an adaptive immune response, which in turn 
prevented further vascularization and capillary network formation. Previous studies 
working to deplete B cells using anti-CD20 helped improve islet survival, specifically by 
inducing the recruitment of regulatory T cells and downregulating T cell function (Rosa 
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Figure 11. CD3 Stains for Group 1: Presence of T Cells Between Days 1-14 Post-
Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) Day 7 
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Figure 12. CD3 Stains for Group 2: Presence of T Cells Between Days 1-7 Post-
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Figure 13. CD3 Stains for Group 3: Presence of T Cells Between Days 1-14 Post-
Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) Day 7 
Post-Implantation. (D.) Day 14 Post-Implantation. 
 
Figures 11-13 show representative images of slides stained with the T cell marker 
CD3, and indicate the presence of T cells, in all three groups post-implantation. Over 
time, there appears to be an increase in the population of T cells surrounding the scaffold 
remnant in all three groups. In the adaptive immune response, once T cells are activated, 
they work with macrophages and other immune cells to phagocytose foreign microbes. 
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We believe that this is what happened with all three groups, as over time, the scaffolds 
seem to both degrade. Additionally, we believe that the immune response helped kill off 
the islets in the parenchymal space, and T cells have been implicated in islet destruction 
post-transplantation (Lewis et al. 2002). Specifically, CD8+ cytotoxic T cells, which are 
activated by Th1 helper T cells, work to destroy pancreatic tissue and lead to increased 
islet destruction over time (Uno et. al, 2007). 
F4-80  
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Figure 14. F4-80 Stains for Group 1: Presence of Macrophages Between Days 1-14 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
Day 7 Post-Implantation. (D.) Day 14 Post-Implantation. 
 
43 
  A.                                                            B. 
      
C.                                                                D. 
     
     E. 
 
Figure 15. F4-80 Stains for Group 2: Presence of Macrophages Between Days 1-28 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
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Figure 16. F4-80 Stains for Group 3: Presence of Macrophages Between Days 1-28 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 




 Figures 14-16 show representative images of slides stained with the macrophage 
marker F4-80, indicating the presence of macrophages, in all three groups post-
implantation. As previously stated, macrophages are indicative of inflammation, and can 
lead to both islet loss and poor vascularization. There is no clear presence of endothelial 
cells nor islets surrounding all remnants of the scaffold. This could be indicative of poor 
islet seeding, however based on the macrophages’ role in secreting chemotactic factors 
that recruit inflammatory cells such as IL-1 and acting as phagocytes (Nackiewicz et. al, 
2020), this could potentially have led to islet dysfunction and loss. 
M1 macrophages, which actively work to kill pathogens, were likely more present 
than M2 macrophages, which are pro-angiogenic and work to downregulate the immune 
response and participate in wound healing (Jackute et. al, 2018). While there was a 
significant presence of fibrosis, based on the lack of vascular network formation and 
increased presence of phagocytic activity, there seems to be an abundance of M1 
macrophages. CD206 has been implicated as a marker for M2 macrophages, however 
was not used in this study to differentiate between the resident macrophage populations 
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Figure 17. pDCA-1 Stains for Group 1: Presence of Plasmacytoid Dendritic Cells 
Between Days 1-14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-
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Figure 18. pDCA-1 Stains for Group 2: Presence of Plasmacytoid Dendritic Cells 
Between Days 1-7 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-
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Figure 19. pDCA-1 Stains for Group 3: Presence of Plasmacytoid Dendritic Cells 
Between Days 1-7 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-
Implantation. (C.) Day 7 Post-Implantation. 
 
 Figures 17-19 show representative images of slides stained with the dendritic cell 
marker, pDCA-1, showing the presence of plasmacytoid dendritic cells, in all three 
groups post-implantation. Images from Days 14 and 28 are missing, as there was poor 
visualization of the scaffold, however Days 1-7 are present for all three groups. Like the 
previous immune cells mentioned, there seems to be an increase in dendritic cell 
populations over time, signifying an increased inflammatory response. In Type I diabetes, 
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dendritic cells are known to produce pro-inflammatory cytokines, including TNF-alpha 
and IL-1β, that work to destroy islet cells (Uno et. al, 2007). Additionally, they are able 
to promote innate and specific immunity, and act as antigen-presenting cells for 
recognition by lymphocytes for further destruction (Xue et. al, 2017). In previous studies 
analyzing the impact of dendritic cells on islet survival post-transplantation, the presence 
of dendritic cells led to islet destruction four weeks post-transplantation, and a decreased 
ability to produce sufficient insulin to restore normoglycemia (Haase et. al, 2004). 
Therefore, we believe that the presence of dendritic cells surrounding the scaffold led to 
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Figure 20. Ly6G Stains for Group 1: Presence of Neutrophils Between Days 1-14 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
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Figure 21. Ly6G Stains for Group 2: Presence of Neutrophils Between Days 1-14 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
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Figure 22. Ly6G Stains for Group 3: Presence of Neutrophils Between Days 1-14 
Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
Day 7 Post-Implantation. (D.) Day 14 Post-Implantation. 
 
 Figures 20-22 show representative images taken of slides stained with neutrophil 
marker Ly6G. These images show the presence of neutrophils, surrounding the scaffold 
for all three groups post-implantation. Based on the Figures 20B, 21B, and 22B, it seems 
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that recruitment of neutrophils increased over time in all three groups, specifically after 
days 1 and 2 post-implantation. Interestingly, the degree of inflammation did not 
significantly vary between any of the groups, suggesting that the inflammatory reaction 
was more in response to the scaffold material rather than whether cells were present in 
the scaffold or not. This indicated the presence of a potent innate immune reaction in 
response to the scaffold (Kanak et. Al, 2014). We believe that the increased inflammation 
brought upon by the neutrophils was involved in helping prevent the formation of a 
capillary network to help ensure the islets received the nutrients and oxygen they needed 
to survive and function properly. In 2014, Diana and Lehuen conducted a study analyzing 
the impact of neutrophils on islet viability, showing that chemokines, including CXCL1 
and CXCL2, work in recruiting neutrophils to the surrounding islet tissue (Diana and 
Lehuen, 2014). By working to inhibit the actions of these chemokines, they were 
successful in reducing the diabetogenic T-cell response and further incidence of diabetes 
(Diana and Lehuen, 2014). This shows that, if the inflammatory response is diminished, 
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Figure 23. Anti-Vimentin antibodies were used to analyze Group 1: Presence of 
Fibroblasts Between Days 1-14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) 
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Figure 24. Anti-Vimentin antibodies were used to analyze Group 2: Presence of 
Fibroblasts Between Days 1-14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) 















A.                          B. 
    
 
   C.                                         D. 
     
Figure 25. Anti-Vimentin antibodies were used to analyze Group 3: Presence of 
Fibroblasts Between Days 1-14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) 
Day 2 Post-Implantation. (C.) Day 7 Post-Implantation. (D.) Day 14 Post-Implantation. 
 
 
 Figures 23-25 show representative images taken of slides stained with the 
fibroblast marker Vimentin, indicating the presence of fibroblasts, in all three groups 
post-implantation. The presence of fibroblasts surrounding the scaffold indicates 
increased inflammation, which appears to increase over time similarly to other immune 
cell populations. Previous studies have also used this marker to express the inflammatory 
reaction, with increased expression over subsequent days post-transplantation; it was seen 
to increase 12-fold between days 1 and 5 after transplanting up to 2,000 islets in the right 
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kidney capsule of diabetic rats (Vasir et. al, 2000). An abundance of fibroblasts can 
indicate fibrosis, and negatively impact vascular formation and the islet’s ability to 
properly secrete insulin when in need. This has been proven in studies analyzing islet 
durability post-transplantation when fibrosis is present (Divanyan et. al, 2019). While the 
presence of fibroblasts has been shown to improve revascularization of islets transplanted 
subcutaneously, there must be a strong vascular network formed immediately after the 
islets are transplanted, as the fibrotic response will instead become pathological and 
contribute to the inflammatory reaction (Perez-Basterrechea et. al, 2017). We believe that 
this was the case with our scaffolds, as the lack of proper vascularization, hypoxemia, 
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Figure 26. vWF Stains for Group 1: Presence of Endothelial Cells Between Days 1-
14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
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Figure 27. vWF Stains for Group 2: Presence of Endothelial Cells Between Days 1-
28 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
Day 7 Post-Implantation. (D.) Day 14 Post-Implantation. (E.) Day 28 Post-Implantation. 
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Figure 28. vWF Stains for Group 3: Presence of Endothelial Cells Between Days 1-
14 Post-Implantation. (A.) Day 1 Post-Implantation. (B.) Day 2 Post-Implantation. (C.) 
Day 7 Post-Implantation. (D.) Day 14 Post-Implantation. 
 
 Figures 26-28 show representative images taken of slides stained with von 
Willebrand Factor (vWF), which indicates the presence of endothelial cells, in all three 
groups post-implantation. We believed that the presence of the foreign body reaction 
impeded the formation of a vascular network between the scaffold and the tissue in all 
three groups, and hence, further graft integration. Our objective was to test whether any 
vasculature would form upon implantation of the scaffold, and after analyzing the images 
above, we concluded that poor endothelial cell seeding, hypoxemia, and the increased 
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foreign body reaction all contributed to poor vascular network formation. We believe 
that, when conducting Groups 2 and 3 over again, and better ensuring all the endothelial 
cells properly seed into the vascular space of the scaffold, we can more efficiently 
promote angiogenesis, and hence, islet survival. 
 For Group 1, there was no presence of a capillary network formed for any of the 
timepoints shown. This is likely due to the complications mentioned above, and did not 
allow for optimal graft integration and perfusion. For Groups 2 and 3, we saw some 
presence of a capillary network formed within the first two days post-implantation, 
however failed to achieve vascularization after these time points. By Days 14 and 28, 
there was no vasculature present, which did not allow for proper diffusion of oxygen and 













A.                                                                  B. 
          
      C. 
 
Figure 29. Insulin Marker for Group 3. (A.) Day 2 Post-Implantation. (B.) Day 14 
Post-Implantation. (C.) Day 28 Post-Implantation. The following three figures depict 
insulin stains conducted on specified days to analyze the presence of islets in the 
parenchymal space of the scaffold. Images for Days 1 and 7 showed poor visualization of 
the scaffold, and are therefore not shown in the figure.  
 
 
 Figure 29 shows representative images taken of slides stained with insulin to 
analyze the presence of islets in the scaffolds for Group 3. Images for Days 1 and 7 are 
not present due to poor visualization of the scaffold in the pictures taken for those days. 
As can be seen, islets are not visibly present in most images, with only islet remnants 
present in Day 2 post-implantation, shown in Figure 29A. Based on the report from the 
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Histolopathology Core of the Department of Transplantation at MGH, the insulin stains 
came back negative, indicating that the islets died soon after implantation, and that they 
did not survive to produce sufficient insulin in any of the mice. We believe that, with 
better islet seeding and a more optimal microvascular environment, the islets would 
obtain the nutrients they needed to provide improved insulin secretion and in turn, 
improved glucose control, as seen in previous studies implanting prevascularized devices 






















 The objective of our study was to analyze whether inserting a prevascularized 
device, along with islets in the parenchymal space, would promote islet survival. When 
seeding the endothelial cells into the vascular space and the islets into the parenchymal 
space, careful attention was placed to make sure all cells were properly placed into their 
respective compartments. However, the size of the scaffolds was smaller than anticipated, 
and it was a challenge to optimize the seeding of 300-400 islets into the parenchymal 
space. Had we better accounted for the size of the scaffolds after the first group, and 
conducted histology on a scaffold before implanting to ensure the islets had seeded 
correctly, we would have been able to better understand how the graft integrated 
subcutaneously, and more definitively determine whether rejection had occurred based on 
the number of endothelial cells and islets present in the scaffold. 
 
VASCULAR NETWORK FORMATION 
 Previous studies on islet transplantation have shown the importance of the 
formation of a vascular network immediately after transplanting islets into diabetic 
recipients (Giatromanolaki et. al, 1997). It was imperative for us to ensure that 
microvasculature was visible to better enable islet survival. While minor capillary 
networks were visible in Groups 2 and 3 during Days 1 and 2 post-implantation, we 
believe that the vasculature was not sufficient enough to promote islet survival, as 
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minimal islets were present in the images eliciting the insulin stains. While the 
inflammatory response and hypoxemia have a severe impact in maintaining islet 
durability, it is essential to make sure the islets can have nutrients easily perfused with the 
rest of the body. This was shown in previous studies whereby microvasculature formation 
was found 21-days post-islet transplantation, enabling proper insulin secretion and 
glucose control (Vlahos et. al, 2017). When conducting Groups 2 and 3 once again, with 
optimal seeding, we believe that we can substantially improve islet durability 
subcutaneously on a more long-term basis. 
 
INFLAMMATORY RESPONSE 
Surprisingly, the immune response did not significantly vary between the 
vascularized scaffolds without islets and the vascularized scaffolds with islets. This was 
most likely because the immune response was more so in response to the implantation of 
the foreign scaffold material rather than to the presence of cells. Additionally, as 
previously mentioned, because we lacked proper seeding of the islets and endothelial 
cells, it is difficult to conclude if enough cells were present in the scaffolds to trigger a 
more rigorous immune response, in comparison to the acellular scaffolds. This could be 
why the foreign body reaction was similar in all three groups. 
This differed from our initial hypothesis, which stated that the addition of islets 
would trigger increased leukocyte integration, and therefore, cause a more potent 
inflammatory reaction. According to a study completed by Wang. et. al studying the 
impact of an immune response on the body’s microvasculature post-islet transplantation, 
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after transplanting islets into a murine kidney capsule, leukocytes appeared to invade the 
surrounding tissue, causing a reduction in the size of the vascular network and negatively 
affecting capillary permeability (Wang et. al, 2013). This hindered the ability of the islets 
to release insulin, and in proper delivery of oxygen and nutrients throughout the body. 
This related to our study, in that the rejection of the scaffold compromised the tissue’s 
ability to fully vascularize and promote islet survival. 
 
INFLAMMATORY SCORE 
 An inflammatory score was established to quantify the level of immune cell 
recruitment, proceeding inflammation, and any fibrosis present surrounding the scaffold 
post-implantation. This has also been completed in previous studies looking into better 
understanding an inflammatory reaction (Max et. al, 2016). Specifically, one study 
conducted blindly by pathologists at the Medical University in Austria analyzed the level 
of tumor budding as a predictor of colorectal cancer, assigning a similar scoring system 
to indicate the various levels of inflammation and presence of immune cells (Max et. al, 
2016).  Another study conducted by the Armed Forces Institute of Pathology in 
Washington, D.C. similarly assigned grades of inflammation and fibrosis seen in the 
development of chronic liver disease (Goodman, 2007). The studies mentioned were used 
to help create a score breakdown and ensure all important cell lines were properly 
assessed. 
 Of all the primary cells present, macrophages and neutrophils were seen to be 
most heavily recruited surrounding the scaffold post-implantation. As part of the innate 
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immune system, they are known to induce inflammation that can negatively impact islet 
viability and function (Kanak et. al, 2014). A score of 2 was assigned, indicating that the 
macrophages and neutrophils filled up around the focal interfaces of the scaffold, 
spreading out and inducing inflammation to compromise islet durability. For our studies, 
we believe that that this was a primary reason for islet engraftment failure early on post-
implantation. 
 While macrophages and neutrophils were seen to be heavily recruited to the site 
surrounding the scaffold over the specified time points, lymphocytes were also present, 
albeit to a lesser extent. They were assigned a score of 1, indicating that they increased 
over time to the site of implantation, however were scattered around the scaffold to a 
lesser degree. 
 Lastly, the level of fibrosis was assigned a score of 3, indicating the presence of 
the numerous cell lines surrounding the scaffold. The level of fibrosis increased most 
remarkably in the first two days post-implantation, indicating a more potent innate 
inflammatory reaction. While we considered giving immunosuppressive treatments, such 
as tacrolimus, to better protect against immune cell recruitment and the proceeding 
inflammation, previous studies had shown mice experiencing severe complications from 
such treatments, including hypertension, dizziness, and diarrhea (Didion, 2011). 
 
LIMITATIONS OF THE STUDY 
 
 While useful data were obtained in this study, as with any investigation, there 
were some limitations. Firstly, the physiology of mice is similar to that of humans, 
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however it is not as exact as that of other larger animals, such as nonhuman primates, 
which may limit the reliability of the data. Additionally, while islet isolations and 
transplants are fairly common procedures to assess islet graft survival, our study involved 
inserting a prevascularized device with both a vascular and islet compartment, which had 
not previously been completed before. While we successfully implanted the scaffolds 
subcutaneously, we saw significant inflammation and a large population of diverse 
immune cells, which could have led to both islet and endothelial cell death, and hence, 
graft rejection. Lastly, because the endothelial and islet cell compartments were fairly 
small, it was often difficult to confirm that the cells fully seeded into the parenchymal 
space of the scaffold. To account for this, further islet isolations were conducted to 




 After analyzing the H&E staining and immunohistochemistry from Groups 2 and 
3, we feel it is best to conduct those implants again, with specific modifications to better 
ensure the scaffolds are vascularized and the islets remain intact both pre-and-post-
implantation. Prior to implantation, we plan on creating two scaffolds (one with and one 
without islets), and sending them for histological analysis to ensure that both the 
endothelial cells and islets are present in the vascular and parenchymal spaces, 
respectively. This will be essential in confirming that the endothelial cell and islet 
seeding process were successful prior to implanting the scaffolds subcutaneously. 
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 Once we confirm that the endothelial cells and islets are viable and present in the 
scaffolds, we will implant them, wait the allotted time points chosen, and explant them 
for further histological analysis and immunohistochemical staining. We feel that this will 
help us better understand both the capillary networks formed, any ensuing inflammatory 
response, and their impact on islet survival. 
 Lastly, our plan in the near future is to implant the prevascularized scaffolds into 
Type I diabetic mice and evaluate their glycemic control post-implantation. This would 
confirm the viability of the islets, and whether there is proper insulin delivery to best 
regulate glucose metabolism. For our current study, we wanted to firstly evaluate the 
vascular network formed and any accompanying inflammatory reactions experienced by 
the tissue after implantation of the scaffolds, and how to best keep the islets viable once 




 Based on the data collected over the course of this study, we believe more 
emphasis must be placed on finding optimal locations for islet transplantation that can 
most effectively lead to improved revascularization. This will help better facilitate 
insulin, oxygen, and nutrient delivery, and lead to proper blood glucose control in 
diabetic recipients. Additionally, a big challenge for us was to determine whether an 
immune response or lack of proper islet seeding was the cause for diminished islet 
engraftment. To better understand the immune response based on the histological analysis 
of the immune cell proliferation surrounding the scaffold, we suggest that the use of 
immunosuppressive agents, such as tacrolimus or etanercept that have been shown to 
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protect against rejection of islet engraftment, can better rule out an immune response and 
help improve islet seeding (Anazawa et. al, 2018).  
 
CONCLUSION 
Our study demonstrated that a prevascularized device implanted subcutaneously 
can work to improve islet graft survival and durability in a murine model. In assessing the 
data collected, we believe that inserting a prevascularized device, with endothelial cells in 
the vascular space and islets in the parenchymal space, can restore islet function and 
better help regulate blood sugar levels in diabetic recipients. With further research, we 
hope that this could serve as a supplement to the continuous use of insulin injections and 
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